Outcomes of off-label drug uses in hospitals: a multicentric prospective study

[1]  A. Vallano,et al.  Utilización hospitalaria de medicamentos en condiciones diferentes a las aprobadas en la ficha técnica , 2014 .

[2]  M. Joerger,et al.  Off-label use of anticancer drugs in eastern Switzerland: a population-based prospective cohort study , 2014, European Journal of Clinical Pharmacology.

[3]  M. Gatto,et al.  In-/off-label use of biologic therapy in systemic lupus erythematosus , 2014, BMC Medicine.

[4]  K. Urbánek,et al.  Incidence of unlicensed and off-label prescription in children , 2014, Italian Journal of Pediatrics.

[5]  J. Seale.  Off‐label prescribing , 2014, The Medical journal of Australia.

[6]  A. Vallano,et al.  [Off-label drug use in hospitals]. , 2014, Medicina clinica.

[7]  Munir Pirmohamed,et al.  Adverse drug reactions and off-label and unlicensed medicines in children: a nested case?control study of inpatients in a pediatric hospital , 2013, BMC Medicine.

[8]  P. Pillans,et al.  Experience with low‐dose rituximab in off‐label indications at two tertiary hospitals , 2013, Internal medicine journal.

[9]  C. Liddle,et al.  Prospective data collection of off‐label use of rituximab in Australian public hospitals , 2013, Internal medicine journal.

[10]  R. Bordet,et al.  Prescriptions hors-AMM : comment en pratique les identifier, les encadrer, informer et les suivre ? , 2013 .

[11]  P. Jolliet,et al.  Off-label prescriptions: how to identify them, frame them, announce them and monitor them in practice? , 2013, Therapie.

[12]  J. Bosch,et al.  Available evidence and outcome of off-label use of rituximab in clinical practice , 2013, European Journal of Clinical Pharmacology.

[13]  T. Casale,et al.  Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. , 2013, The New England journal of medicine.

[14]  A. Kesselheim,et al.  FDA regulation of off-label drug promotion under attack. , 2013, JAMA.

[15]  B. Roehr.  Free speech rights outweigh restrictions on promoting drugs off label, court rules , 2012, BMJ : British Medical Journal.

[16]  J. Mellor,et al.  Access to anticancer drugs: many evidence‐based treatments are off‐label and unfunded by the Pharmaceutical Benefits Scheme , 2012, Internal medicine journal.

[17]  R. Shimazawa,et al.  Japanese regulatory system for approval of off-label drug use: evaluation of safety and effectiveness in literature-based applications. , 2012, Clinical therapeutics.

[18]  Cristina Casanovas,et al.  Intervención educativa en pacientes con epilepsia ingresados en la Unidad de Monitorización de Epilepsia del Hospital Universitari Germans Trias i Pujol , 2012 .

[19]  David L Buckeridge,et al.  Drug, patient, and physician characteristics associated with off-label prescribing in primary care. , 2012, Archives of internal medicine.

[20]  A. Kesselheim,et al.  The Prevalence and Cost of Unapproved Uses of Top-Selling Orphan Drugs , 2012, PLoS ONE.

[21]  E. Pérez-Pampín,et al.  Safety and retention rate of off-label uses of TNF antagonists in rheumatic conditions: data from the Spanish registry BIOBADASER 2.0. , 2011, Rheumatology.

[22]  Sanjay Sharma.  LEVELS OF EVIDENCE , 2007 .

[23]  Joan Costa,et al.  Use of non-specific intravenous human immunoglobulins in Spanish hospitals; need for a hospital protocol , 2010, European Journal of Clinical Pharmacology.

[24]  R. Labianca,et al.  Off-Label Prescription of Antineoplastic Drugs: An Italian Prospective, Observational, Multicenter Survey , 2009, Tumori.

[25]  H. Kokki,et al.  Off‐label and unlicensed drug prescribing in three paediatric wards in Finland and review of the international literature , 2009, Journal of clinical pharmacy and therapeutics.

[26]  W. Shao,et al.  Systematic review and meta-analysis of randomized controlled trials comparing botulinum toxin injection with lateral internal sphincterotomy for chronic anal fissure , 2009, International Journal of Colorectal Disease.

[27]  C. Heneghan,et al.  Levels of Evidence , 2008 .

[28]  E. Cheek,et al.  Botulinum toxin vs glyceryltrinitrate for the medical management of chronic anal fissure: a meta‐analysis , 2008, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[29]  R. Labianca,et al.  Metronomic Chemotherapy in Elderly Patients: Do Risks Exceed Benefits in Some Patients? , 2007, Tumori.

[30]  T. Hampton.  Experts weigh in on promotion, prescription of off-label drugs. , 2007, JAMA.

[31]  R. Stafford,et al.  Off-label prescribing among office-based physicians. , 2006, Archives of internal medicine.

[32]  H. Tobi,et al.  Risk factors for unlicensed and off-label drug use in children outside the hospital. , 2003, Pediatrics.

[33]  B. Stricker,et al.  Unlicensed and off-label drug use in a paediatric ward of a general hospital in the Netherlands , 2002, European Journal of Clinical Pharmacology.